[go: up one dir, main page]

PE20160746A1 - Composicion farmaceutica que comprende aleglitazar - Google Patents

Composicion farmaceutica que comprende aleglitazar

Info

Publication number
PE20160746A1
PE20160746A1 PE2016000386A PE2016000386A PE20160746A1 PE 20160746 A1 PE20160746 A1 PE 20160746A1 PE 2016000386 A PE2016000386 A PE 2016000386A PE 2016000386 A PE2016000386 A PE 2016000386A PE 20160746 A1 PE20160746 A1 PE 20160746A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
refers
happiness
includes happiness
aleglitazar
Prior art date
Application number
PE2016000386A
Other languages
English (en)
Inventor
Paul Wojtera
Alexander Glomme
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20160746A1 publication Critical patent/PE20160746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se refiere a una composicion farmaceutica que contiene 0,01 mg a 0,9 mg de aleglitazar, que es el acido (S)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxazol-4-il)-etoxi]-benzo[b]tiofen-7-il}-propionico. Tambien se refiere a un proceso de fabricacion. Dicha composicion es util en el tratamiento o profilaxis de enfermedades cardiovasculares o diabetes tipo II.
PE2016000386A 2009-01-23 2010-01-13 Composicion farmaceutica que comprende aleglitazar PE20160746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09151254 2009-01-23

Publications (1)

Publication Number Publication Date
PE20160746A1 true PE20160746A1 (es) 2016-08-01

Family

ID=42112184

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001309A PE20120421A1 (es) 2009-01-23 2010-01-13 Composicion farmaceutica que comprende aleglitazar
PE2016000386A PE20160746A1 (es) 2009-01-23 2010-01-13 Composicion farmaceutica que comprende aleglitazar

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001309A PE20120421A1 (es) 2009-01-23 2010-01-13 Composicion farmaceutica que comprende aleglitazar

Country Status (25)

Country Link
US (2) US20100190835A1 (es)
EP (1) EP2389166B1 (es)
JP (1) JP5619027B2 (es)
KR (2) KR20140002812A (es)
CN (1) CN102292074B (es)
AR (1) AR075041A1 (es)
AU (1) AU2010206249B2 (es)
BR (1) BRPI1007237B1 (es)
CA (1) CA2748896C (es)
CL (1) CL2011001777A1 (es)
CY (1) CY1113641T1 (es)
DK (1) DK2389166T3 (es)
ES (1) ES2397558T3 (es)
HR (1) HRP20130108T1 (es)
IL (1) IL213671A (es)
MX (1) MX2011007381A (es)
PE (2) PE20120421A1 (es)
PL (1) PL2389166T3 (es)
PT (1) PT2389166E (es)
RU (1) RU2537224C2 (es)
SG (1) SG173058A1 (es)
SI (1) SI2389166T1 (es)
TW (1) TWI406861B (es)
WO (1) WO2010084066A1 (es)
ZA (1) ZA201104670B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
WO2014016369A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Pharmaceutical formulation comprising aleglitazar and complexing agent
WO2014016371A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Micronized aleglitazar
WO2014016370A1 (en) * 2012-07-27 2014-01-30 Ratiopharm Gmbh Amorphous aleglitazar
MX2015002095A (es) * 2012-09-12 2015-05-11 Hoffmann La Roche Formas solidas de acido (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxaz ol-4-il)-etoxi]benzo[b]tiofen-7-il}propionico y de sales del mismo.
CN116172869A (zh) * 2016-08-10 2023-05-30 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
CN114404375B (zh) * 2022-01-21 2023-06-27 武汉九珑人福药业有限责任公司 一种叶酸固体制剂及其原料组合物、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
MXPA03010435A (es) * 2001-05-15 2004-03-09 Hoffmann La Roche Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
KR20070094666A (ko) * 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
FR2894477A1 (fr) * 2005-12-13 2007-06-15 Galderma Res & Dev Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US20100210692A1 (en) * 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators

Also Published As

Publication number Publication date
RU2011134964A (ru) 2013-02-27
JP5619027B2 (ja) 2014-11-05
AR075041A1 (es) 2011-03-02
US20130072529A1 (en) 2013-03-21
CA2748896A1 (en) 2010-07-29
US20100190835A1 (en) 2010-07-29
SI2389166T1 (sl) 2013-02-28
ZA201104670B (en) 2012-03-28
DK2389166T3 (da) 2012-12-17
KR20110105798A (ko) 2011-09-27
RU2537224C2 (ru) 2014-12-27
PL2389166T3 (pl) 2013-04-30
ES2397558T3 (es) 2013-03-07
BRPI1007237B1 (pt) 2019-05-28
KR20140002812A (ko) 2014-01-08
AU2010206249A1 (en) 2011-06-30
CN102292074A (zh) 2011-12-21
TWI406861B (zh) 2013-09-01
PE20120421A1 (es) 2012-05-04
AU2010206249B2 (en) 2015-07-09
IL213671A (en) 2015-11-30
EP2389166B1 (en) 2012-11-21
CL2011001777A1 (es) 2012-02-24
CA2748896C (en) 2017-01-03
CN102292074B (zh) 2013-08-21
HRP20130108T1 (hr) 2013-03-31
SG173058A1 (en) 2011-08-29
IL213671A0 (en) 2011-07-31
JP2012515741A (ja) 2012-07-12
MX2011007381A (es) 2011-08-12
BRPI1007237A2 (pt) 2016-02-16
WO2010084066A1 (en) 2010-07-29
TW201035089A (en) 2010-10-01
EP2389166A1 (en) 2011-11-30
PT2389166E (pt) 2013-01-08
CY1113641T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
PE20160746A1 (es) Composicion farmaceutica que comprende aleglitazar
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
UY32032A (es) "2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](io, oxi o amino)-n-(heteroaril)alcanamidas"
PE20110136A1 (es) Compuestos organicos
EA201071144A1 (ru) Гетероциклические производные
CL2009000628A1 (es) Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
CU23551B7 (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
GT201200164A (es) "nuevos compuestos de espiropiperidina"
ECSP10010416A (es) Forma de dosificación farmaceutica
PE20170306A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
EA201100969A1 (ru) Солевые формы органического соединения
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
PE20080153A1 (es) Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
BR112015012909A2 (pt) compostos de ácido borônico de triazol substituído
PE20120324A1 (es) Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
CL2011002345A1 (es) Proceso de obtencion del acido (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxazol-4-il)-etoxi]-benzo[b]tiofen-7-il}-propionico utilizando un catalizador de iridio.